Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
2
|
| pubmed:dateCreated |
1998-4-23
|
| pubmed:abstractText |
Prolymphocytic leukemia (PLL) is a rare lymphoproliferative disorder that takes a rapidly progressive course and where therapeutic interventions are often unsuccessful. In this context, the new purine analogs may be a promising option. We report two cases of PLL treated with cladribine. The first patient had been resistant to polychemotherapy (COP) but responded well to two courses of 2-CdA. He achieved a partial remission, which he maintained for 15 months. The second patient had very advanced disease but obtained a partial response after three courses of 2-CdA, given as a first-line therapy in an ambulatory setting. These results, as well others reported in the literature, permit us to consider 2-CdA as a highly promising therapeutic option for PLL.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Feb
|
| pubmed:issn |
0939-5555
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
76
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
85-6
|
| pubmed:dateRevised |
2006-11-15
|
| pubmed:meshHeading | |
| pubmed:year |
1998
|
| pubmed:articleTitle |
Treatment of prolymphocytic leukemia with cladribine.
|
| pubmed:affiliation |
Department of Internal Medicine, Faculty of Medicine, Brazil.
|
| pubmed:publicationType |
Journal Article,
Case Reports,
Research Support, Non-U.S. Gov't
|